An efficient, versatile linker is developed for the synthesis of C-terminal primary/secondary amides and hydrazides as well as peptide alcohols, which is compatible with solid-phase peptide synthesis (SPPS) and suppresses side reactions. It is termed as Ramage Linker.
The basis for the Ramage linker is a dibenzocyclohepta-1,3-dienyl system with an additional oxygen substituent which serves on one hand for further stabilization. The Ramage linker represents an alternative to the commonly used Rinklinker for the synthesis of C-terminal peptide amides. The three-circular structure of the Ramage linker prevents its fragmentation cleavage from the resin followed by back alkylation. This is a drawback commonly observed during peptide synthesis with the Rinklinker. Consequently, the Ramage linker delivers peptides in higher purity with less impurities compared to peptides produced with the Rinklinker.
Besides C-terminal amides, the Ramage linker can also be used for the synthesis of C-terminal peptide alcohols.
Their diverse biological activities and clinical importance are described in various publications. One prominent example is Octreotide, a metabolically stable analog of somatostatin which contains threoninol at the C-terminus. Starting from the Ramage linker or resin, the deprotected primary amine can be converted to a hydroxy moiety and further to the corresponding chloride, which can then be loaded with Fmoc-amino alcohols. Analogous to the preparation of peptide amides, the synthesized sequence can be detached from the linker and fully deprotected by conventional reagents.
References:
- Design of a versatile linker for solid phase peptide synthesis: Synthesis of C-terminal primary / secondary amides and hydrazides; R. Ramage, S. L. Irving and C. McInnes; Tetrahedron Lett 1993; 34: 6599-6602
- Functionalized Resins for the Synthesis of Peptide Alcohols; F. J. Ferrer Gago, L. Q. Koh, D. P. Lane; Chem. Eur. J. 2020; 26(2): 379-383
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.
Advanced Drug Delivery Systems Market, valued at USD 234.84 billion in 2023, is on a trajectory of significant growth, projected to reach USD 352.01 billion by 2032
The U.S. Food and Drug Administration on January 15, 2025, announced its decision to ban Red Dye No. 3 also referred to as Erythrosine.
Targeted drug delivery revolutionises treatment by focusing medications on specific tissues, reducing the impact on healthy cells. Scientists enhance this precision with carriers like microspheres and nanoparticles, controlling release and absorption. Microspheres, made from biodegradable proteins or polymers, sustain drug release, making them ideal for targeted therapies, especially in oncology. Beyond drug delivery, microspheres open new possibilities across industries—from next-gen coatings to thermal insulation. With tailored sizes, shapes, and materials, they drive advancements in pharmaceuticals, advanced materials, and more.
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing cosmetics for asbestos. The FDA noted that this move aims to protect consumers from potential harm posed by asbestos, a known carcinogen linked to serious illnesses such as lung and ovarian cancers.